ClinicalTrials.gg
Status unknownNCT04383977Updated May 12, 2020

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

A Phase 2 interventional study of Apatinib and Etoposide capsule and Apatinib in Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing apatinib in Ovarian Neoplasms — 6 open to participants now, 6 under way, 1 of them phase 3. apatinib · Ovarian Neoplasms.

Planned enrollment
13th of 22
54 · median 59
Started
2020
with 3 others
Phase 2
15 of 22
4 open now
Registered
14th of 22
by date
Lead sponsor
5 of 22
Jiangsu HengRui Medicine Co., Ltd.

Among the 22 studies testing apatinib in Ovarian Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2020, is one of 15 in phase 2, and was the 14th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 22 studies testing apatinib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing apatinib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients, ≥18 Years.
  2. Epithelial ovarian, fallopian tube or primary peritoneal cancer
  3. Platinum and resistant disease (disease progression during platinum therapy or within \<6 months of platinum therapy)
  4. EOCG performance status of 0-2

Exclusion criteria

Exclusion Criteria:

  1. Non-epithelial tumours
  2. Ovarian tumours with low malignant potential
  3. Surgery (including open ) within 4 weeks before starting study therapy or anticipated need for major surgery during study treatment
  4. Evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Apatinib-Etoposide capsule

    Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity

    Drug: Apatinib and Etoposide capsule

  • Active comparator
    Apatinib

    Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity

    Drug: Apatinib

Interventions

  • DrugApatinib and Etoposide capsule

    Drug pages: Apatinib · Etoposide

    Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity

  • Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) by investigator

    ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline .

    Time frame: up to 2 years

Secondary outcomes

  1. AEs+SAEs

    Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0

    Time frame: 30 days after the last dose

  2. PFS by investigator

    PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria.

    Time frame: up to 2 years

  3. Overall Survival (OS)

    OS is the time interval from the date of randomization to death from any cause.

    Time frame: up to 3 years

  4. Pharmacokinetic characteristic

    Evaluation of PK parameters Tmax of apatinib or etoposide in plasma

    Time frame: up to 2 years

  5. Pharmacokinetic characteristic

    Evaluation of PK parameters Cmax of apatinib or etoposide in plasma

    Time frame: up to 2 years

  6. Pharmacokinetic characteristic

    Evaluation of PK parameters t1/2 of apatinib or etoposide in plasma

    Time frame: up to 2 years

  7. Pharmacokinetic characteristic

    Evaluation of PK parameters AUC0-t of apatinib or etoposide in plasma

    Time frame: up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2020; primary completion for Dec 2020, 7 months later.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 7 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 12, 2020
StartEst.
May 2020
Primary completionEst.
Dec 2020
CompletionEst.
Jun 2021
Last update
May 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04383977
Responsible party
Sponsor
First posted
May 12, 2020
Start date
May 2020 (estimated)
Primary completion
Dec 2020 (estimated)
Completion
Jun 2021 (estimated)
Last update
May 12, 2020

Study contacts

Zhaoyu Zhong, M.M
Contact
zhongzhaoyu@hrglobe.cn
+86 15045090779
Fenglin She, M.M
Contact
shefenglin@hrglobe.cn
+86 18301190515

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Etoposide

Start the discussion